Polyphor AG

  • ISIN: CH0106213793
  • Land: Schweiz

Nachricht vom 04.09.2019 | 17:38

Polyphor to present at the H.C. Wainwright Global Investment Conference

EQS Group-News: Polyphor AG / Key word(s): Conference

04.09.2019 / 17:38


Allschwil, Switzerland, September 4, 2019

Polyphor to present at the H.C. Wainwright Global Investment Conference

Polyphor AG (SIX: POLN) today announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City. Giacomo Di Nepi, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A live webcast of the presentation will be accessible on Polyphor's website on the Investor Relations page on the Calendar tab or under the following link: Polyphor Webcast. A replay of the webcast will be available for 90 days following the conclusion of the event.


Presentation details:
Date: September 9, 2019
Time: 03:25 - 03:50pm EDT
Location: The Lotte Palace Hotel, New York
Webcast: Polyphor Webcast


For further information please contact:

For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com


For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=SOIKULNSGV
Document title: Polyphor_Wainwright_4.9.2019


End of Corporate News



show this

ESG-Whitepaper im Fokus

The Corporate ESG Guide: A 360 view on the current landscape and trends

Die ESG-Kriterien (Environmental, Social and Governance) werden auch für Emittenten immer wichtiger, wenn sie für Investoren attraktiv bleiben wollen. In dem Whitepaper “The Corporate ESG Guide: A 360 view on the current landscape and trends” beantworten die Experten von Investor Update grundlegende Fragen von Emittenten. Außerdem kommen Vermögensverwalter, Unternehmensberater Manager und ESG-Ratingagenturen zu wichtigen ESG-Themen zu Wort.

GBC-Fokusbox

"GBC Best of m:access 2020": Neue vielversprechende Auswahl

Unsere letztjährige „GBC Best of m:access“-Auswahl hat sich mit einer Performance von über 50 % überdurchschnittlich stark entwickelt und alle relevanten Indizes hinter sich gelassen. Im Rahmen der vorliegenden aktualisierten Studie präsentieren wir Ihnen eine in Teilen neu zusammengesetzte Selektion, die weiterhin 15 Unternehmen umfasst. Die aktuellen Einschätzungen zu den Einzeltiteln und auch weitere Informationen zur Entwicklung des m:access sind in der vollständigen Studie „GBC Best of m:access 2020“ enthalten.

News im Fokus

Vonovia SE: Vonovia kauft 1.000 Wohnungen in Kiel (News mit Zusatzmaterial)

02. Dezember 2020, 18:01

Aktueller Webcast

ADLER Group S.A.

Neunmonats-
Investor Call
Q3 2020

30. November 2020

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

02. Dezember 2020